Boston Scientific Co. (NYSE:BSX) is Parkman Healthcare Partners LLC’s 4th Largest Position

Parkman Healthcare Partners LLC reduced its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 24.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 337,354 shares of the medical equipment provider’s stock after selling 109,842 shares during the period. Boston Scientific comprises 4.0% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 4th biggest position. Parkman Healthcare Partners LLC’s holdings in Boston Scientific were worth $30,132,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Boston Scientific by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider’s stock valued at $11,869,805,000 after purchasing an additional 1,600,062 shares during the last quarter. Wellington Management Group LLP lifted its position in Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock worth $3,230,293,000 after buying an additional 3,344,571 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Boston Scientific by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock valued at $2,729,371,000 after buying an additional 1,041,329 shares in the last quarter. Capital World Investors grew its stake in shares of Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock valued at $2,492,041,000 after buying an additional 6,216,199 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Boston Scientific by 2.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider’s stock worth $1,992,994,000 after buying an additional 554,388 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares in the company, valued at $2,704,845.33. The trade was a 4.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the sale, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 267,021 shares of company stock valued at $27,534,636 in the last quarter. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on BSX. Stifel Nicolaus upped their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Barclays increased their target price on Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Needham & Company LLC increased their target price on Boston Scientific from $113.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, April 24th. Argus set a $130.00 price objective on Boston Scientific in a research report on Tuesday, February 18th. Finally, Truist Financial lifted their target price on Boston Scientific from $113.00 to $117.00 and gave the stock a “buy” rating in a research report on Thursday, April 24th. Twenty-three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $114.52.

Boston Scientific Trading Up 0.0%

Shares of Boston Scientific stock opened at $102.92 on Wednesday. The firm has a market cap of $152.26 billion, a PE ratio of 82.34, a PEG ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a 50 day simple moving average of $98.69 and a two-hundred day simple moving average of $96.24. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the previous year, the firm earned $0.56 EPS. The company’s quarterly revenue was up 20.9% compared to the same quarter last year. Analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.